Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | POLG | P54098 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128447 | 0.96 | FGFR1 (0.48) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL7125876 | 0.94 | FGFR1 (0.49) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL6664903 | 0.91 | FGFR1 (0.50) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL7125887 | 0.91 | FGFR1 (0.45) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL7123639 | 0.90 | FGFR1 (0.47) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL6846424 | 0.89 | FGFR1 (0.53) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL7129073 | 0.89 | FGFR1 (0.48) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL7127274 | 0.87 | FGFR1 (0.53) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL7125992 | 0.86 | FGFR1 (0.46) | FGFR1SLC22A6CYP2C19POLBSLC29A1 | |
| SCHEMBL7769858 | 0.86 | SLC29A1 (0.46) | CYP2C19SLC29A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109498-A1 | Antiviral agent for drug-resistant virus | MITSUBISHI PHARMA CORPORATION (JP) | 2003-06-12 | — | — | US | claimed |
| US-20030109498-A1 | Antiviral agent for drug-resistant virus | MITSUBISHI PHARMA CORPORATION (JP) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109498-A1 | Antiviral agent for drug-resistant virus | TPMT, MTAP, TYMP | FGFR1 1401/4885SLC22A6 399/4885CYP2C19 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.